Miguel J. Lanz MD , Bradley E. Chipps MD , Robert S. Zeiger MD, PhD , Leonard B. Bacharier MD , Theresa W. Guilbert MD , Kevin R. Murphy MD , Tonya Winders MBA , Acklema Mohammad MD , Monique LeNoir MA , Ileen Gilbert MD , James M. Eudicone MS, MBA , Karin S. Coyne PhD, MPH , Gale Harding MA , Maureen George PhD, RN
{"title":"Pediatric Asthma Impairment and Risk Questionnaire","authors":"Miguel J. Lanz MD , Bradley E. Chipps MD , Robert S. Zeiger MD, PhD , Leonard B. Bacharier MD , Theresa W. Guilbert MD , Kevin R. Murphy MD , Tonya Winders MBA , Acklema Mohammad MD , Monique LeNoir MA , Ileen Gilbert MD , James M. Eudicone MS, MBA , Karin S. Coyne PhD, MPH , Gale Harding MA , Maureen George PhD, RN","doi":"10.1016/j.anai.2024.11.021","DOIUrl":"10.1016/j.anai.2024.11.021","url":null,"abstract":"<div><h3>Background</h3><div>Asthma in children is a leading cause of missed school days, emergency department visits, and hospitalizations. Approximately 40% of children with asthma experience uncontrolled disease and annual exacerbations. There is a need for a validated composite tool for children, such as the Asthma Impairment and Risk Questionnaire (AIRQ), which was developed to assess current control and predict exacerbations in adolescents and adults with asthma.</div></div><div><h3>Objective</h3><div>To obtain feedback from children with asthma and their parents/caregivers to inform development of a version of the AIRQ for pediatric use (Peds-AIRQ).</div></div><div><h3>Methods</h3><div>Children with asthma aged 5 to 11 years and their parents/caregivers participated in cognitive interviews to elicit language describing asthma symptoms and exacerbations and to assess understanding and relevance of draft Peds-AIRQ questions. Physicians and parents/caregivers provided clinical information and performed assessments relative to the children's asthma morbidity.</div></div><div><h3>Results</h3><div>There were 60 dyads that participated: children's mean (SD) age = 7.9 (1.9) years; 68% male, 45% non-White, 32% Hispanic, and 40% with public health insurance. Overall, 53% had well-controlled, 30% partly controlled, and 17% uncontrolled asthma, based on the Global Initiative for Asthma symptom control questions. Oral or injected corticosteroids were used for asthma by 53% of the children in the previous year. Participants found draft Peds-AIRQ items understandable and relevant. Seven impairment and 3 risk questions were retained for validation, along with 5 additional items containing wording or control threshold variations.</div></div><div><h3>Conclusion</h3><div>This study supports the need for developing a composite (impairment and risk) control tool to assess children aged 5 to 11 years with asthma and identified suitable questions for the validation of a Peds-AIRQ.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 2","pages":"Pages 198-208.e2"},"PeriodicalIF":5.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthew R. Elliott MD, Anna E. O'Connor MD, Gailen D. Marshall MD, PhD
{"title":"Corrigendum to ‘Inflammatory pathways in patients with post-acute sequelae of COVID-19’ [Annals of Allergy, Asthma & Immunology 133/5 (2024) 507 – 515]","authors":"Matthew R. Elliott MD, Anna E. O'Connor MD, Gailen D. Marshall MD, PhD","doi":"10.1016/j.anai.2024.11.026","DOIUrl":"10.1016/j.anai.2024.11.026","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 2","pages":"Page 243"},"PeriodicalIF":5.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Osteonecrosis: A disabling disease not to be ignored in asthma and atopic conditions","authors":"Chase P. Rupprecht MD , Guha Krishnaswamy MD","doi":"10.1016/j.anai.2024.10.025","DOIUrl":"10.1016/j.anai.2024.10.025","url":null,"abstract":"<div><div>Osteonecrosis, also referred to as avascular necrosis, is a disease characterized by necrosis or death of a bone secondary to impairment in blood supply. The condition affects the epiphyseal ends of the bones such as the femur and the humerus, but it can also involve the metacarpal and metatarsal bones, the patella, the knee, the vertebrae, and the jaw. A plethora of inflammatory, autoimmune, hematological, thrombotic, and vascular diseases can lead to osteonecrosis. Corticosteroids are intimately linked to the development of osteonecrosis. The frequent use of systemic corticosteroids in patients with asthma, eczema, nasal polyposis, sinusitis, urticaria and angioedema, or anaphylaxis makes this disease of great relevance to the practicing allergist and pulmonologist. Untreated, bone necrosis leads to frustrated bone remodeling and angiogenesis, leading to subchondral fractures and collapse of the articular heads of the bones, and culminating in debilitating osteoarthritis, often requiring arthroplasty. Recent studies have shed light on the molecular mechanisms underlying osteonecrosis and on the role of glucocorticoids. The gold standard test in patients suspected of having the disease is magnetic resonance imaging scanning, with plain radiographs having a lower sensitivity and specificity. Early diagnosis and intervention are essential. The allergist should avoid the frequent use of glucocorticoids and consider early introduction of steroid-sparing alternatives for asthma or sinusitis. Smoking and alcohol ingestion need to be addressed, and the management of glucocorticoid-induced osteoporosis may be helpful. It is essential for allergists to familiarize themselves with the disease and its diagnosis and to consider early referral to an orthopedic surgeon for surgical intervention.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 2","pages":"Pages 165-176"},"PeriodicalIF":5.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marcello Cottini MD , Carlo Lombardi MD , Pasquale Comberiati MD , Alvise Berti MD , Francesco Menzella MD , Ronald J. Dandurand MD , Zuzana Diamant MD, PhD , Rory Chan MBChB, PhD
{"title":"Oscillometry-defined small airways dysfunction as a treatable trait in asthma","authors":"Marcello Cottini MD , Carlo Lombardi MD , Pasquale Comberiati MD , Alvise Berti MD , Francesco Menzella MD , Ronald J. Dandurand MD , Zuzana Diamant MD, PhD , Rory Chan MBChB, PhD","doi":"10.1016/j.anai.2024.11.006","DOIUrl":"10.1016/j.anai.2024.11.006","url":null,"abstract":"<div><div>The small airways, also referred to as the lung's silent zone, are closely associated with poor symptom control and more frequent asthma exacerbations. The oscillometry technique superimposes sound or airwaves onto normal tidal breathing and provides information on resistance and reactance, that is, obstacles to airflow occurring inside and outside of the bronchi. More recently, a management paradigm based on so-called “treatable traits” has been proposed to personalize and improve asthma care for individuals by proactively identifying and targeting modifiable pulmonary, extrapulmonary, and behavioral traits affecting asthma control. In this review article, we evaluate the literature on small airways dysfunction as a potential treatable trait in persistent asthma. In particular, we discuss whole- and intrabreath oscillometry and the impact of extrafine inhaled corticosteroids and systemic biologics on the peripheral airways.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 2","pages":"Pages 151-158"},"PeriodicalIF":5.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification","authors":"Thomas Bieber MD, PhD, MDRA","doi":"10.1016/j.anai.2024.09.022","DOIUrl":"10.1016/j.anai.2024.09.022","url":null,"abstract":"<div><div>The recent development of new therapies for atopic dermatitis (AD) has greatly benefited from the advances in understanding the mechanisms underlying this disease. This progress now allows one to envisage pushing the therapeutic boundaries beyond the simple symptomatic treatment of the exacerbations of AD and considering new therapeutic strategies aimed to allow an off-therapy long-term and deep remission, that is, disease modification. Owing to the complexity of the phenotype and underlying mechanisms of AD, it is expected that this will not fit to the current one-size-fits-all model in drug development. Thus, aiming at disease modification will lead to a paradigm shift in drug development strategy in AD requiring the consideration of a precision medicine approach with a phenotype-endotype (biomarker)-based stratification as well as a consensus definition of specific study endpoints for the clinical development program. This review addresses the scientific rationale for this strategy, some general aspects of the design of confirmatory clinical trials, and the variables along the Population, Intervention, Comparator, and Outcome framework to be addressed for reaching the ultimate goal of disease modification in AD.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 2","pages":"Pages 144-150"},"PeriodicalIF":5.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laurie A. Manka MD , Vamsi P. Guntur MD, MSc , Allen D. Stevens BA , Christena Kolakowski MS , Camille M. Moore PhD , Richard J. Martin MD
{"title":"The Supraglottic Index","authors":"Laurie A. Manka MD , Vamsi P. Guntur MD, MSc , Allen D. Stevens BA , Christena Kolakowski MS , Camille M. Moore PhD , Richard J. Martin MD","doi":"10.1016/j.anai.2024.10.012","DOIUrl":"10.1016/j.anai.2024.10.012","url":null,"abstract":"<div><h3>Background</h3><div>Laryngopharyngeal reflux (LPR) is associated with gastroesophageal reflux and is known to cause poor asthma control. Moreover, LPR and asthma frequently coexist in the same individual. Controlling LPR could be associated with improved asthma control. The Supraglottic Index (SGI) is a clinically applied visual scale, which correlates with the presence of LPR. The role of SGI in monitoring LPR therapy in individuals with asthma is not known.</div></div><div><h3>Objective</h3><div>To determine whether the SGI can be used over time to assess the presence of LPR in patients with asthma, and whether the SGI improves with LPR treatment.</div></div><div><h3>Methods</h3><div>This is a pilot study in 15 participants with asthma. Those without evidence of LPR by SGI measurement were assigned to the observation arm. Those with LPR were assigned to the treatment arm and were treated with either standard-of-care LPR treatment (antacids and behavioral management) or a novel therapy (upper esophageal assist device).</div></div><div><h3>Results</h3><div>The SGI remained stable in individuals with asthma who underwent observation over 8 weeks. The SGI improved in participants with asthma treated for LPR (<em>P</em> = .024).</div></div><div><h3>Conclusion</h3><div>The SGI is a readily available clinical tool to assess the presence of LPR and monitor its therapy in asthma.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 2","pages":"Pages 209-214.e2"},"PeriodicalIF":5.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}